{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T22:59:45Z","timestamp":1775429985857,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41440-025-02524-1","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:50:57Z","timestamp":1767768657000},"page":"1441-1447","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility study protocol for the evaluation of home blood pressure in patients receiving angiogenesis inhibitor therapy: a multicenter observational study"],"prefix":"10.1038","volume":"49","author":[{"given":"Kaori","family":"Kitaoka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Minegishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Shioyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Shiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Tajiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Fukata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Akazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikio","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"2524_CR1","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","volume":"40","author":"KM Sturgeon","year":"2019","unstructured":"Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40:3889\u201397.","journal-title":"Eur Heart J"},{"key":"2524_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/379252","volume":"2013","author":"KH Fraeman","year":"2013","unstructured":"Fraeman KH, Nordstrom BL, Luo W, Landis SH, Shantakumar S. Incidence of new-onset hypertension in cancer patients: a retrospective cohort study. Int J Hypertens. 2013;2013:379252.","journal-title":"Int J Hypertens"},{"key":"2524_CR3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/j.ackd.2021.09.011","volume":"28","author":"P Gudsoorkar","year":"2021","unstructured":"Gudsoorkar P, Ruf R, Adnani H, Safdar K, Sparks MA. Onco-hypertension: an emerging specialty. Adv Chronic Kidney Dis. 2021;28:477\u201389 e1.","journal-title":"Adv Chronic Kidney Dis"},{"key":"2524_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/HYPERTENSIONAHA.120.16044","volume":"77","author":"S Kidoguchi","year":"2021","unstructured":"Kidoguchi S, Sugano N, Tokudome G, Yokoo T, Yano Y, Hatake K, et al. New concept of onco-hypertension and future perspectives. Hypertension. 2021;77:16\u201327.","journal-title":"Hypertension"},{"key":"2524_CR5","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1093\/ckj\/sfad195","volume":"16","author":"S Pandey","year":"2023","unstructured":"Pandey S, Kalaria A, Jhaveri KD, Herrmann SM, Kim AS. Management of hypertension in patients with cancer: challenges and considerations. Clin Kidney J. 2023;16:2336\u201348.","journal-title":"Clin Kidney J"},{"key":"2524_CR6","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1161\/HYP.0000000000000224","volume":"80","author":"JB Cohen","year":"2023","unstructured":"Cohen JB, Brown NJ, Brown SA, Dent S, van Dorst DCH, Herrmann SM, et al. Cancer therapy-related hypertension: a scientific statement from the American Heart Association. Hypertension. 2023;80:e46\u2013e57.","journal-title":"Hypertension"},{"key":"2524_CR7","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1161\/01.CIR.0000155238.70797.4E","volume":"111","author":"RS Scotland","year":"2005","unstructured":"Scotland RS, Madhani M, Chauhan S, Moncada S, Andresen J, Nilsson H, et al. Investigation of vascular responses in endothelial nitric oxide synthase\/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo. Circulation. 2005;111:796\u2013803.","journal-title":"Circulation"},{"key":"2524_CR8","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1161\/HYPERTENSIONAHA.109.129973","volume":"54","author":"CS Facemire","year":"2009","unstructured":"Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension. 2009;54:652\u20138.","journal-title":"Hypertension"},{"key":"2524_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1161\/HYPERTENSIONAHA.110.168120","volume":"58","author":"EL Mayer","year":"2011","unstructured":"Mayer EL, Dallabrida SM, Rupnick MA, Redline WM, Hannagan K, Ismail NS, et al. Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension. 2011;58:85\u201392.","journal-title":"Hypertension"},{"key":"2524_CR10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","volume":"71","author":"AK Pandey","year":"2018","unstructured":"Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, et al. Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease. Hypertension. 2018;71:e1\u2013e8.","journal-title":"Hypertension"},{"key":"2524_CR11","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41440-024-02086-8","volume":"48","author":"F Si","year":"2025","unstructured":"Si F, Ma X, Liu Q, Yu J. Reviewing the path to balance: mechanisms and management of hypertension associated with targeting vascular endothelium in cancer therapy. Hypertens Res. 2025;48:1034\u201347.","journal-title":"Hypertens Res"},{"key":"2524_CR12","first-page":"372","volume":"12","author":"LJ Costa","year":"2003","unstructured":"Costa LJ, Varella PC, Del Giglio A. White coat effect in breast cancer patients undergoing chemotherapy. Eur J Cancer Care (Engl). 2003;12:372\u20133.","journal-title":"Eur J Cancer Care (Engl)"},{"key":"2524_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1056\/NEJMc072330","volume":"358","author":"M Azizi","year":"2008","unstructured":"Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med. 2008;358:95\u20137.","journal-title":"N Engl J Med"},{"key":"2524_CR14","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1634\/theoncologist.2010-0002","volume":"16","author":"O Mir","year":"2011","unstructured":"Mir O, Coriat R, Cabanes L, Ropert S, Billemont B, Alexandre J, et al. An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist. 2011;16:1325\u201332.","journal-title":"Oncologist"},{"key":"2524_CR15","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jaccao.2019.11.009","volume":"1","author":"JB Cohen","year":"2019","unstructured":"Cohen JB, Geara AS, Hogan JJ, Townsend RR. Hypertension in Cancer patients and survivors: epidemiology, diagnosis, and management. JACC CardioOncol. 2019;1:238\u201351.","journal-title":"JACC CardioOncol"},{"key":"2524_CR16","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41440-024-02072-0","volume":"48","author":"T Maruhashi","year":"2025","unstructured":"Maruhashi T, Tatsumi Y, Satoh M, Kobayashi Y, Ogoyama Y, Sakima A, et al. Updated meta-analysis for antihypertensive treatment guided by home blood pressure compared to treatment based on office blood pressure: systematic review. Hypertens Res. 2025;48:1839\u201345.","journal-title":"Hypertens Res"},{"key":"2524_CR17","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41440-024-01981-4","volume":"48","author":"M Satoh","year":"2025","unstructured":"Satoh M, Tatsumi Y, Nakayama S, Shinohara Y, Kawazoe M, Nozato Y, et al. Self-measurement of blood pressure at home using a cuff device for change in blood pressure levels: systematic review and meta-analysis. Hypertens Res. 2025;48:574\u201391.","journal-title":"Hypertens Res"},{"key":"2524_CR18","unstructured":"Committee of the Japanese Society of Hypertension Guidelines. The Japanese Society of Hypertension Guidelines for the Management of Elevated Blood Pressure and Hypertension 2025 (JSH2025). Tokyo, 2025."},{"key":"2524_CR19","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1016\/j.jacc.2021.04.009","volume":"77","author":"VU Rao","year":"2021","unstructured":"Rao VU, Reeves DJ, Chugh AR, O\u2019Quinn R, Fradley MG, Raghavendra M, et al. Clinical approach to cardiovascular toxicity of oral antineoplastic agents: JACC state-of-the-art review. J Am Coll Cardiol. 2021;77:2693\u2013716.","journal-title":"J Am Coll Cardiol"},{"key":"2524_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/annonc\/mdn637","volume":"20","author":"M Scartozzi","year":"2009","unstructured":"Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2009;20:227\u201330.","journal-title":"Ann Oncol"},{"key":"2524_CR21","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1097\/COC.0000000000000108","volume":"39","author":"S Pant","year":"2016","unstructured":"Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, et al. Treatment-related hypertension as a pharmacodynamic biomarker for the efficacy of bevacizumab in advanced pancreas cancer: a pooled analysis of 4 prospective trials of gemcitabine-based therapy with bevacizumab. Am J Clin Oncol. 2016;39:614\u20138.","journal-title":"Am J Clin Oncol"},{"key":"2524_CR22","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/s41440-025-02149-4","volume":"48","author":"K Shibata","year":"2025","unstructured":"Shibata K, Akasaki Y, Tokushige A, Nitta M, Kawasoe S, Kubozono T, et al. Blood pressure elevations post-lenvatinib treatment in hepatocellular carcinoma: a potential marker for better prognosis. Hypertens Res. 2025;48:1542\u201353.","journal-title":"Hypertens Res"},{"key":"2524_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40885-022-00197-3","volume":"28","author":"X Zhu","year":"2022","unstructured":"Zhu X, Wu S. Risks and management of hypertension in cancer patients undergoing targeted therapy: a review. Clin Hypertens. 2022;28:14.","journal-title":"Clin Hypertens"},{"key":"2524_CR24","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/jnci\/djr128","volume":"103","author":"BI Rini","year":"2011","unstructured":"Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011;103:763\u201373.","journal-title":"J Natl Cancer Inst"},{"key":"2524_CR25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028050","volume":"12","author":"DCH van Dorst","year":"2023","unstructured":"van Dorst DCH, Kabadayi S, Oomen-de Hoop E, Danser AHJ, Mathijssen RHJ, Versmissen J. Treatment and implications of vascular endothelial growth factor inhibitor-induced blood pressure rise: a clinical cohort study. J Am Heart Assoc. 2023;12:e028050.","journal-title":"J Am Heart Assoc"},{"key":"2524_CR26","unstructured":"Common Toxicity Criteria Program. Common Toxicity Criteria, Version2.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcv20_4-30-992.pdf. Accessed 10 Oct 2024."},{"key":"2524_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/MLR.0000000000001664","volume":"60","author":"JA Teresi","year":"2022","unstructured":"Teresi JA, Yu X, Stewart AL, Hays RD. Guidelines for designing and evaluating feasibility pilot studies. Med Care. 2022;60:95\u2013103.","journal-title":"Med Care"},{"key":"2524_CR28","doi-asserted-by":"crossref","unstructured":"Huang RS, Chen D, Benour A, Cortez R, Mihalache A, Johnny C, et al. Patient-reported outcomes as prognostic indicators for overall survival in cancer: a systematic review and meta-analysis. JAMA Oncol. 2025;11:1303\u201312.","DOI":"10.1001\/jamaoncol.2025.3153"},{"key":"2524_CR29","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","volume":"89","author":"CS Cleeland","year":"2000","unstructured":"Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000;89:1634\u201346.","journal-title":"Cancer"},{"key":"2524_CR30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/sj.jhh.1001307","volume":"16","author":"T Tanaka","year":"2002","unstructured":"Tanaka T, Okamura T, Miura K, Kadowaki T, Ueshima H, Nakagawa H, et al. A simple method to estimate populational 24-h urinary sodium and potassium excretion using a casual urine specimen. J Hum Hypertens. 2002;16:97\u2013103.","journal-title":"J Hum Hypertens"},{"key":"2524_CR31","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1291\/hypres.27.755","volume":"27","author":"T Ohkubo","year":"2004","unstructured":"Ohkubo T, Obara T, Funahashi J, Kikuya M, Asayama K, Metoki H, et al. Control of blood pressure as measured at home and office, and comparison with physicians\u2019 assessment of control among treated hypertensive patients in Japan: First Report of the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) study. Hypertens Res. 2004;27:755\u201363.","journal-title":"Hypertens Res"},{"key":"2524_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41416-019-0481-y","volume":"121","author":"C Plummer","year":"2019","unstructured":"Plummer C, Michael A, Shaikh G, Stewart M, Buckley L, Miles T, et al. Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK. Br J Cancer. 2019;121:109\u201316.","journal-title":"Br J Cancer"},{"key":"2524_CR33","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1038\/s41440-024-01660-4","volume":"47","author":"Y Suzuki","year":"2024","unstructured":"Suzuki Y, Kaneko H, Okada A, Fujiu K, Takeda N, Morita H, et al. Risk of cancer history in cardiovascular disease among individuals with hypertension. Hypertens Res. 2024;47:1871\u201380.","journal-title":"Hypertens Res"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02524-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02524-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02524-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T22:14:44Z","timestamp":1775427284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02524-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2524"],"URL":"https:\/\/doi.org\/10.1038\/s41440-025-02524-1","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M.M. has received speaking honoraria from Daiichi Sankyo, Ferring Pharmaceuticals and Janssen Pharmaceutical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}